智通财经APP获悉，维升药业-B(02561)涨超5%，截至发稿，涨5.39%，报46.9港元，成交额217.21万港元。
消息面上，5月12日，维升药业宣布其在研的用于治疗软骨发育不全(achondroplasia, ACH)的那韦培肽(Navepegritide, TransCon CNP)中国2期临床试验已全部顺利完成(包括52周双盲治疗期以及52周开放标签扩展阶段)，并于近期在国家药监局“药物临床试验登记与信息公示平台”登记临床试验结果信息。据悉，那韦培肽中国2期临床试验针对中国2至10岁ACH患儿，采用每周一次皮下给药的方式，旨在安全治疗剂量下持续提供活性CNP。
此外，维升药业近期就公司基本面及核心产品管线的发展状况与投资者进行了深入交流，其中提到，那韦培肽是潜在的相关地区儿童软骨发育不全的同类首创疾病修复疗法，目前国内尚无同类产品获批，且无其他公司在进行相关研发。公司计划将该药物的适应症设计覆盖从儿童诊断开始至15岁的整个生长发育阶段。鉴于患者治疗周期长达十几年，且市场独占性明显，该产品未来有望实现数亿元的年销售额。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.